WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. II: Side effects and women's perceptions

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 111, Issue 7, 2004, Pages 715-725

  Honkanen, Helena ^a   Piaggio, Gilda ^b   Von Hertzen, Helena ^b   Bártfai, Gyorgy ^c   Erdenetungalag, Radnaabazar ^d   Gemzell Danielsson, Kristina ^e   Gopalan, Sarala ^f   Horga, Mihai ^g   Jerve, Fridtjof ^h   Mittal, Suneeta ⁱ   Ngoc, Nguyen Thi Nhu ^j   Peregoudov, Alexandre ^b   Prasad, R N V ^k   Pretnar Darovec, Alenka ^l   Shah, Rashmi S ^m   Song, Si ⁿ   Tang, Oi Shan ^o   Wu, Shang Chun ^p  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF SZEGED   (Hungary)

^d Matern/Child Health Research Center   (Mongolia)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^g Center of Public Health   (Romania)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁱ ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^j Hung Vuong Hospital   (Viet Nam)

^k NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^l Univ Dept of Obstet and Gynaecol   (Slovenia)

^m Institute for Research in Reproduction India   (India)

ⁿ SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^o QUEEN MARY HOSPITAL   (Hong Kong)

^p NATIONAL RESEARCH INSTITUTE FOR FAMILY PLANNING   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; MIFEPRISTONE; MISOPROSTOL; PARACETAMOL; PLACEBO;

ABDOMINAL PAIN; AMENORRHEA; ARTICLE; BLOOD PRESSURE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; EDEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GYNECOLOGIC INFECTION; HEADACHE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PERCEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REACTION TIME; SIDE EFFECT; THERAPEUTIC ABORTION; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 3042703309     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2004.00153.x     Document Type: Article

References (20)

1. El-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995;332:983-987.
2. von Hertzen H, Honkanen H, Piaggio G, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy. Br J Obstet Gynaecol 2003;110:808-818.
3. World Health Organization. Task Force on Post-Ovulatory Methods of Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. Br J Obstet Gynaecol 2000;107:524-530.
4. Ngai SW, Tang OS, Ho PC. Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. Hum Reprod 2000;15:2205-2208.
5. Schaff EA, Stadalius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. J Fam Pract 1997;44:353-360.
6. Tang OS, Gao PP, Cheng L, Lee S, Ho PC. Pilot study on the use of a two-week course of oral misoprostol in patients after termination of pregnancy with mifepristone and misoprostol. Contraception 1998;57:89-91.
7. Gouk EV, Lincoln K, Khair A, Haslock J, Knight J, Cruickshank DJ. Medical termination of pregnancy at 63 to 83 days gestation. Br J Obstet Gynaecol 1999;106:535-539.
8. Weeks A, Stewart P. The use of low dose mifepristone and vaginal misoprostol for first trimester termination of pregnancy. Br J Fam Plan 1995;106:85-86.
9. Harper C, Ellertson C, Winikoff B. Could American women use mifepristone-misoprostol pills safely with less medical supervision? Contraception 2002;65:133-142.
10. Elul B, Hajri S, Ngoc NN, et al. Can women in less-developed countries use a simplified medical abortion regimen? Lancet 2001;357:1402-1405.
11. AHFS. AHFS Drug Information. Bethesda: American Society of Health-System Pharmacists, 2002:2849-2855.
12. Ayres-de-Campos D, Teixeira-da-Silva J, Campos I, Patricio B. Vaginal misoprostol in the management of first-trimester missed abortions. Int J Gynaecol Obstet 2000;71:53-57.
13. Wong KS, Ngai CS, Yeo EL, Tang LC, Ho PC. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod 2000;15:709-712.
14. WHO-UMC (WHO Collaborating Centre for International Drug Monitoring). Available: http://www.who-umc.org. Search on adverse reactions to misoprostol, performed in May 2002.
15. Ramsey PS, Hogg BB, Savage KG, Winkler DD, Owen J. Cardiovascular effects of intravaginal misoprostol in the mid trimester of pregnancy. Am J Obstet Gynecol 2000;183:1100-1102.
16. Gemzell Danielsson K, Marions L, Rodriguez A, Spur BW, Wong PY, Bygdeman M. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol 1999;93:275-280.
17. Jensen JT, Harvey SM, Beckman LJ. Acceptability of suction curett-age and mifepristone abortion in the United States: a prospective comparison study. Am J Obstet Gynecol 2000;182:1292-1299.
18. Winikoff B, Sivin I, Coyaji KJ, et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion. Am J Obstet Gynecol 1997;176:431-437.
19. Henshaw RC, Naji SA, Russell IT, Templeton AA. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. BMJ 1993;307:714-717.
20. Schaff EA, Fielding SL, Eisinger SH, Stadalius LS, Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception 2000;61:41-46.